It would explain why he repetitively whines on and on, day in,...

It would explain why he repetitively whines on and on, day in, day out on these threads about CUV, without even actually talking about it in any insightful sense.

Disc Medicine (IRON) vs Clinuvel (CUV) — Valuation Comparison

	Metric	Disc Medicine (IRON)	Clinuvel (CUV)
Exchange	NASDAQ	ASX
Share price (recent)	~USD $66	~AUD $9
Market cap	~USD $2.5B	~AUD $450M (~USD $316M)
Sales Revenue (TTM - Trailing Twelve Month)	~$0 (pre-revenue)	~AUD $96M
Earnings (TTM)	Loss (~$230M EBITDA burn)	Profit (~AUD $32M net)
EPS	-$6.01	+AUD $0.70
P/E ratio	N/A (loss-making!)	~17x
Cash on hand	~USD $791M	~AUD $234M (~USD $164M)
Dividend	None	AUD $0.05
52-week range	$30.82–$99.50	AUD $9.41–$15.99

Were CUV traded on NASDAQ and a US stock, it might be 4-5 times the mkt cap, and were IRON traded on the ASX and an Aussie company, it might be half the cap - Disc Medicine does have a healthy amount of cash on hand, but it does exist in the far more capital accommodative markets of the USA and would not have that cash were it in Aussie mkts of course.

Ludicrous.